Comparison of 3-Factor Versus 4-Factor Prothrombin Complex Concentrate With Regard to Warfarin Reversal, Blood Product Use, and Costs

被引:18
|
作者
DeAngelo, Jessica [1 ]
Jarrell, Daniel [1 ]
Cosgrove, Richard [1 ]
Camamo, James [1 ]
Edwards, Christopher [1 ]
Patanwala, Asad E. [2 ]
机构
[1] Banner Univ Med Ctr Tucson, Dept Pharm Serv, Tucson, AZ USA
[2] Univ Arizona, Dept Pharm Practice & Sci, Coll Pharm, Tucson, AZ USA
关键词
anticoagulants; warfarin; blood coagulation factors; hemorrhage; INTERNATIONAL NORMALIZED RATIO; CONSENSUS GUIDELINES; THROMBOSIS;
D O I
10.1097/MJT.0000000000000643
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Prothrombin complex concentrates (PCCs) are drug products containing varying amounts of vitamin K-dependent coagulation factors II, VII, IX, and X. The evidence comparing 3-factor PCC (3-PCC) versus 4-factor PCC (4-PCC) for warfarin reversal is conflicting. It has been hypothesized that 3-PCC may be less effective than 4-PCC because of relatively lower factor VII content. Study Question: The primary objective of this study was to compare international normalized ratio (INR) reversal between 3-PCC and 4-factor PCC (4-PCC) in warfarin-treated patients. The secondary objectives include comparing blood product use, total reversal costs, and cost-effectiveness between the groups. Study Design: This was a retrospective cohort study conducted in 2 affiliated, academic institutions in the United States. Consecutive adult patients who received 3-PCC or 4-PCC for warfarin reversal were included. Measures and Outcomes: The primary outcome was adequate INR reversal defined as a final INR <= 1.5. Secondary outcomes were the utilization of plasma, red blood cells and platelets, reversal costs, and the cost-effectiveness ratio. Results: There were 89 patients who were included in the overall cohort (3-PCC = 57, 4-PCC = 32). Adequate INR reversal occurred less commonly with 3-PCC (45.6%) compared with 4-PCC (87.5%) (P < 0.001). There was no significant difference in the proportion of patients who received plasma (32% vs. 28%, P = 0.813), red blood cells (37% vs. 47%, P = 0.377), or platelets (16% vs. 28%, P = 0.180) between the 3-PCC and 4-PCC groups, respectively. The median reversal cost of 3-PCC ($3663) was lower than 4-PCC ($5105) (P = 0.001). The cost-effective ratio favored 4-PCC ($5105/87.5% = $5834) compared with 3-PCC ($3663/45.6% = $8033). Conclusions: Four-PCC was more effective than 3-PCC with regard to INR reversal in patients taking warfarin, but blood product use was similar. Although 4-PCC is associated with increased reversal costs, it may be cost-effective in terms of INR reversal.
引用
收藏
页码:E326 / E332
页数:7
相关论文
共 50 条
  • [21] FIXED-DOSE 4-FACTOR PROTHROMBIN COMPLEX CONCENTRATE FOR WARFARIN REVERSAL
    Gomez, Leigh
    Langenhan, Emilie
    Blaha, Madeline
    CRITICAL CARE MEDICINE, 2023, 51 (01) : 379 - 379
  • [22] Comparison of 3-Factor Prothrombin Complex Concentrate and Low-Dose Recombinant Factor VIIa for Warfarin Reversal
    Scott A Chapman
    Eric D Irwin
    Nada M Abou-Karam
    Nichole M Rupnow
    Katherine E Hutson
    Jeffrey Vespa
    Robert M Roach
    World Journal of Emergency Surgery, 9
  • [23] Comparison of 3-Factor Prothrombin Complex Concentrate and Low-Dose Recombinant Factor VIIa for Warfarin Reversal
    Chapman, Scott A.
    Irwin, Eric D.
    Abou-Karam, Nada M.
    Rupnow, Nichole M.
    Hutson, Katherine E.
    Vespa, Jeffrey
    Roach, Robert M.
    WORLD JOURNAL OF EMERGENCY SURGERY, 2014, 9
  • [24] Thrombin generation and thromboelastometry in monitoring the in-vitro reversal of warfarin: a comparison between 3-factor and 4-factor prothrombin complex concentrates
    Spiezia, Luca
    Rossetto, Valeria
    Campello, Elena
    Bulato, Cristiana
    Radu, Claudia M.
    Simioni, Paolo
    BLOOD COAGULATION & FIBRINOLYSIS, 2020, 31 (02) : 127 - 131
  • [25] Evaluation of fixed versus variable dosing of 4-factor prothrombin complex concentrate for emergent warfarin reversal
    Stoecker, Zachary
    Van Amber, Brandon
    Woster, Casey
    Isenberger, Kurt
    Peterson, Marissa
    Rupp, Paula
    Chrenka, Ella
    Dries, David
    AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2021, 48 : 282 - 287
  • [26] Emergent Warfarin Reversal With Fixed-Dose 4-Factor Prothrombin Complex Concentrate
    Jansma, Brianna
    Montgomery, Josephine
    Dietrich, Scott
    Mixon, Mark A.
    Peksa, Gary D.
    Faine, Brett
    ANNALS OF PHARMACOTHERAPY, 2020, 54 (11) : 1090 - 1095
  • [27] Evaluation of fixed dose 4-factor prothrombin complex concentrate for emergent warfarin reversal
    Klein, Lauren
    Peters, Jessica
    Miner, James
    Gorlin, Jed
    AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2015, 33 (09): : 1213 - 1218
  • [28] Activated Prothrombin Complex Concentrate Versus 4-Factor Prothrombin Complex Concentrate for Vitamin K-Antagonist Reversal
    Rowe, A. Shaun
    Dietrich, Scott K.
    Phillips, John W.
    Foster, Kaci E.
    Canter, Joshua R.
    CRITICAL CARE MEDICINE, 2018, 46 (06) : 943 - 948
  • [29] 4-FACTOR PROTHROMBIN COMPLEX CONCENTRATE ADMINISTRATION VIA INTRAOSSEOUS ACCESS FOR URGENT REVERSAL OF WARFARIN
    Peyko, Vincent
    Shams, Darius
    Urbanski, Richard
    Noga, Joseph
    JOURNAL OF EMERGENCY MEDICINE, 2019, 57 (01): : 82 - 84
  • [30] Fixed dose 4-factor prothrombin complex concentrate for the emergent reversal of warfarin: a retrospective analysis
    Astrup, Greta
    Sarangarm, Preeyaporn
    Burnett, Allison
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2018, 45 (02) : 300 - 305